Skip to Content
Morningstar

Cytokinetics Inc CYTK

Morningstar Rating
Unlock
Stock XNAS Rating as of
$67.45 +1.17 (1.77%)
View Full Chart
As of Cboe BZX Real-Time Price Open
Unlock our analysis with Morningstar Investor
Start Free Trial

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

View History
CYTK is trading at a 40% discount.
Price
$65.88
Fair Value
$789.12
Uncertainty
Extreme
1-Star Price
$367.19
5-Star Price
$81.27
Economic Moat
Bqxl
Capital Allocation
—
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CYTK is a good fit for your portfolio.
Get 7 Days Free

News

View All

Trading Information

Previous Close Price
$66.28
Day Range
$67.24–68.68
52-Week Range
$26.00–110.22
Bid/Ask
$67.31 / $67.48
Market Cap
$7.05 Bil
Volume/Avg
226,289 / 2.1 Mil

Key Statistics

Price/Earnings (Normalized)
—
Price/Sales
849.74
Dividend Yield (Trailing)
—
Dividend Yield (Forward)
—
Total Yield
—

Company Profile

Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
564
Website
https://www.cytokinetics.com

Competitors

Valuation

View More
Metric
CYTK
SNY
BMY
Price/Earnings (Normalized)
 —9.566.58
Price/Book Value
 —1.493.37
Price/Sales
 849.742.272.27
Price/Cash Flow
 —11.116.47
Price/Earnings
CYTK
SNY
BMY

Financial Strength

Metric
CYTK
SNY
BMY
Quick Ratio
 6.000.831.24
Current Ratio
 6.121.271.43
Interest Coverage
 −8.6011.038.24
Quick Ratio
CYTK
SNY
BMY

Profitability

Metric
CYTK
SNY
BMY
Return on Assets (Normalized)
 −53.44%8.05%16.56%
Return on Equity (Normalized)
 —14.38%50.88%
Return on Invested Capital (Normalized)
 −93.87%10.85%23.63%
Return on Assets
CYTK
SNY
BMY
See how this stock stacks up to its competitors with Morningstar Investor
Start Free Trial

Biotechnology Industry Comparables

Screen in Investor
Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRVxjzlrnspzCglgq$557.8 Bil
VRTX
Vertex Pharmaceuticals IncVywpmlsdDqwtnp$103.3 Bil
REGN
Regeneron Pharmaceuticals IncNrdybdjgBdfwgt$98.8 Bil
MRNA
Moderna IncDkjybdwpQlms$38.8 Bil
ARGX
argenx SE ADRJbyxqbbKwnsw$21.3 Bil
BNTX
BioNTech SE ADRQmcnsrjgGtnxd$20.8 Bil
ALNY
Alnylam Pharmaceuticals IncFnypqygkRbhqgnf$18.4 Bil
BMRN
Biomarin Pharmaceutical IncKqsknlpkMcnnml$17.0 Bil
RPRX
Royalty Pharma PLC Class AFhxbcdfbfhHzsyq$12.4 Bil
INCY
Incyte CorpRyzfkhvfQffff$11.9 Bil

Sponsor Center